Biolinerx (BLRX) Posts Q1 Loss of 1c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Aegis Keeps BioLineRx (BLRX) at 'Buy'; Plenty of Catalysts Happening Over Next 12 Months
May 21, 2014 9:26 AM EDTAegis Capital maintained BioLineRx, Ltd. (Nasdaq: BLRX) at Buy with a $7 price target following Q1 results. After markets closed Tuesday, BioLineRx reported Q1 EPS of ($0.01), $0.10 better than the analyst estimate of ($0.11).
Analyst Ram Selvaraju said, The firm ended the quarter with $37.5mm in cash, following a recent financing round that raised $24.1mm in net proceeds from the sale of roughly 9.7mm American... More
